Evidence map›Paper›PMID 28096157›Full record

ArticleAntimicrobial agents and chemotherapy2017

Resistance to Thiacetazone Derivatives Active against Mycobacterium abscessus Involves Mutations in the MmpL5 Transcriptional Repressor MAB_4384.

Iman Halloum, Albertus Viljoen, Varun Khanna, Derek Craig, Christiane Bouchier, Roland Brosch, Geoffrey Coxon, Laurent Kremer

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 74 citations in OpenAlex.

  1. Article
  2. Article
  3. Genetic analysis ofiScience · 2026
    Article
  4. Challenges in the Diagnosis and Treatment of Mycobacterium abscessus Infections.Revista da Sociedade Brasileira de Medicina Tropical · 2026
    Review
  5. Review
  6. Article
  7. Structural and functional analysis of theProceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  8. Article
  9. Novel mutations in theAntimicrobial agents and chemotherapy · 2025
    Article
  10. Article
  11. TBAJ-587, a novel diarylquinoline, is active againstAntimicrobial agents and chemotherapy · 2024
    Article
  12. Efflux pump effects on levofloxacin resistance inAntimicrobial agents and chemotherapy · 2024
    Article
  13. Article
  14. Article
  15. Review
  16. Exploring antibiotic resistance mechanisms inFrontiers in microbiology · 2024
    Review
  17. Genome-Scale Characterization ofInternational journal of molecular sciences · 2023
    Article
  18. Characterization ofMicrobiology spectrum · 2023
    Article
  19. MarR-Dependent Transcriptional Regulation ofAntimicrobial agents and chemotherapy · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 2 countries.

Iman HalloumCentre National de la Recherche Scientifique FRE 3689, Centre d'études d'agents Pathogènes et Biotechnologies pour la Santé, Université de Montpellier, Montpellier France.
Albertus ViljoenCentre National de la Recherche Scientifique FRE 3689, Centre d'études d'agents Pathogènes et Biotechnologies pour la Santé, Université de Montpellier, Montpellier France.
Varun KhannaInstitut Pasteur, Hub Bioinformatique et Biostatistique, C3BI, Unité de Services et de Recherche, USR 3756, Institut Pasteur CNRS, Paris, France.
Derek CraigStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom.
Christiane BouchierInstitut Pasteur, PF1 Genopole, Paris, France.
Roland BroschInstitut Pasteur, Unité de Pathogénomique Mycobactérienne Intégrée, Paris, France.
Geoffrey CoxonStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom.
Laurent KremerCentre National de la Recherche Scientifique FRE 3689, Centre d'études d'agents Pathogènes et Biotechnologies pour la Santé, Université de Montpellier, Montpellier France laurent.kremer@cpbs.cnrs.fr.
Université de Montpellier · FRUniversity of Strathclyde · GBCentre d’études d’agents Pathogènes et Biotechnologies Pour la Santé · FRCentre National de la Recherche Scientifique · FRGenopole (France) · FRInstitut Pasteur · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Available chemotherapeutic options are very limited against

Indexed as

Antitubercular AgentsBacterial ProteinsDrug Resistance, BacterialMicrobial Sensitivity TestsMutationMycobacteriumThioacetazoneAntitubercular AgentsBacterial ProteinsThioacetazonedrug resistance mechanismMmpLMycobacterium abscessusTetR regulatortherapeutic activitythiacetazone

Identifiers

PMID28096157
PMCPMC5365672
OpenAlexW2575722488

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.